As cardiovascular co-morbidities are common in diabetes, it is possible that pharmacological activities that target Serca2 in the cardiovascular system and in diabetes may have beneficial effects by increasing cardiac contractility and limiting metabolic disorders. Here, ATP2A2 is linked to Other metabolic disease.